C2i Genomics (MRD)

Monitors minimum residual disease through liquid biopsy so patients can track how their cancer responds.

Vetted listing

Testing

Consented intake · your records travel with you · nothing moves without your sign-off

Why C2i exists

C2i Genomics provides liquid biopsy testing focused on minimum residual disease. It gathers and analyzes blood and other bodily fluids for biomarkers such as DNA, RNA, and proteins that can guide treatment and monitor disease progression. For patients wanting to know whether cancer remains after treatment, this kind of monitoring provides ongoing insight.

Results delivered in weeksDeveloped by VeracyteClinical studies · UMBRELLA trial with Gustave Roussy and the phase 3 multicenter TOMBOLA trial in Denmark

1
Tissue and blood collection
Blood and tissue samples are submitted. Blood is separated into plasma for ctDNA analysis and buffy coat for a normal germline comparison, alongside the tumor tissue sample.
2
Create the tumor signature
Whole genome sequencing analyzes DNA from the tumor tissue and from normal germline cells to identify the cancer specific mutations that form a personalized tumor signature.
3
Establish a baseline
Whole genome sequencing of the plasma sample creates a baseline result that future tests are compared against.
4
Monitor for recurrence
Blood samples collected at later timepoints are compared to the baseline, delivering an estimated tumor fraction and a clear Detected or Not Detected result.

Prefer the source? C2i Genomics (MRD)'s own site has more.

Share your records

We'll pre-fill the intake from your records — no retyping.

Start sharing →

Check your coverage

See if your insurance covers this and estimate out-of-pocket cost.

Check coverage →

Coverage, insurance & cost

The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how C2i Genomics (MRD) handles billing.

We don't have confirmed insurance details for C2i Genomics (MRD) yet. Start a coverage check with your plan, or contact the provider directly.

Common questions about C2i

How does C2i work?

1. Tissue and blood collection — Blood and tissue samples are submitted. Blood is separated into plasma for ctDNA analysis and buffy coat for a normal germline comparison, alongside the tumor tissue sample. 2. Create the tumor signature — Whole genome sequencing analyzes DNA from the tumor tissue and from normal germline cells to identify the cancer specific mutations that form a personalized tumor signature. 3. Establish a baseline — Whole genome sequencing of the plasma sample creates a baseline result that future tests are compared against. 4. Monitor for recurrence — Blood samples collected at later timepoints are compared to the baseline, delivering an estimated tumor fraction and a clear Detected or Not Detected result.

How long does C2i take?

Results delivered in weeks

How do I connect with C2i?

Through OpenCancer's consented intake: enter your details once, choose exactly which records travel with the request, and sign a consent that covers this connection only. Nothing is shared without your sign-off.

Understand this before you decide

Veracyte Patient Resources

Guide from C2i Genomics (MRD)

FAQs for Patients and Caregivers

Guide from C2i Genomics (MRD)

Ask about this service

Answers grounded in C2i's details here. Educational only; your oncologist directs treatment.

Also consider

Other providers in similar categories.

BostonGene

6 offerings

Gather distinctive biomarkers that can guide treatment and monitor disease progression

Foundation Medicine

6 offerings

FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.